- Home
- DSGX vs ERAS Comparison
DSGX vs ERAS Comparison
Compare DSGX & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSGX | ERAS |
|---|---|---|
| Founded | 1981 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.5B |
| IPO Year | 1999 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DSGX | ERAS |
|---|---|---|
| Price | $67.60 | $10.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $105.22 | $14.25 |
| AVG Volume (30 Days) | 473.5K | ★ 8.6M |
| Earning Date | 06-03-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.05 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $37.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $62.56 | $1.06 |
| 52 Week High | $117.35 | $24.28 |
Technical Indicators
Market Signals| Indicator | DSGX | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 41.37 | 36.23 |
| Support Level | $62.69 | $2.07 |
| Resistance Level | $75.06 | $16.14 |
| Average True Range (ATR) | 2.33 | 0.88 |
| MACD | -0.71 | -0.21 |
| Stochastic Oscillator | 22.23 | 59.45 |
Price Performance
Historical ComparisonAbout DSGX Descartes Systems Group Inc. (The)
Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.